On March 11, 2020 Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, reported its fourth quarter 2019 results (Press release, Targovax, MAR 11, 2020, View Source [SID1234555382]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below).
HIGHLIGHTS FOR THE FOURTH QUARTER 2019
In October, Targovax was selected for oral presentation at Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2019 Annual Meeting. The presentation was given by Dr. Alexander Shoushtari, Principal Investigator of ONCOS-102 trial in melanoma, Memorial Sloan Kettering Cancer Center, NYC
POST-PERIOD HIGHLIGHTS
In January 2020, Targovax announced it has entered into an option agreement with IOVaxis Therapeutics for an TG mutant RAS vaccine license and clinical development agreement in China
In January 2020, Targovax presented encouraging data in the mesothelioma study combining ONCOS-102 and standard of care chemotherapy
In January 2020, Targovax successfully completed a private placement, raising gross proceeds of approximately NOK 101 million (USD 11.2 million)
In March, Targovax announced completed enrollment in the ONCOS-102 trial in anti-PD1 refractory melanoma
Øystein Soug, CEO commented: "2019 marked an important milestone for Targovax as we started to see clinical efficacy with ONCOS-102 in combination with checkpoint inhibitors and chemotherapy. With the new data at hand, we have solidified our position as a leader in the oncolytic virus field. While we continue to treat patients and analyze data, we are preparing for the next steps of the ONCOS program beyond the ongoing trials."
Presentation
The presentation will take place at 10:00 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
The presentation will also be webcast live and can be accessed here.
Reporting material
Targvoax 4Q presentation
Targovax 4Q report
The quarterly report and presentation are also available at the website www.targovax.com.